Last reviewed · How we verify
Fampridine-SR
At a glance
| Generic name | Fampridine-SR |
|---|---|
| Also known as | Sustained release 4-aminopyridine, 4-AP, 4-aminopyridine, Fampyra (Ampyra in the US). |
| Sponsor | Acorda Therapeutics |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor (PHASE1)
- 4-aminopyridine Treatment for Nerve Injury (PHASE2, PHASE3)
- Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression (PHASE2)
- A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene (PHASE3)
- Influence of Fampridine on Working Memory in Healthy Subjects (PHASE2)
- Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis (PHASE3)
- Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment (NA)
- Dalfampridine in Egyptian Patients With Multiple Sclerosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fampridine-SR CI brief — competitive landscape report
- Fampridine-SR updates RSS · CI watch RSS
- Acorda Therapeutics portfolio CI